Celgene, Dr. Reddy's Settle Generic Cancer Drug Row
Bristol-Myers Squibb subsidiary Celgene has settled litigation in the U.S. that sought to block Indian drugmaker Dr. Reddy's from marketing generic versions of its blockbuster cancer medication Pomalyst, according to documents...To view the full article, register now.
Already a subscriber? Click here to view full article